The Global Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022

The Global Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022

The Next Generation of Cancer Therapies

RELEASE DATE
19-Jan-2018
REGION
North America
Research Code: MC55-01-00-00-00
SKU: HC02963-NA-MR_21491
AvailableYesPDF Download

$3,000.00

Special Price $2,250.00 save 25 %

In stock
SKU
HC02963-NA-MR_21491

$3,000.00

$2,250.00save 25 %

DownloadLink
ENQUIRE NOW

Description

Immuno-oncology refers to drugs that are used to stimulate the human immune system to target the fight against cancer. The immune system is capable of recognizing and eliminating foreign substances, including tumor cells. Tumors have, however, been able to escape detection by the immune system. There are drugs that can empower the immune system cells to attack tumor cells. Natural Killer (NK) cells are the main cells involved in the natural immune response. Once an immune response is initiated, the immune response can be sustained through memory, called adaptive immunity. Cytotoxic T cells are the main cells involved with adaptive immunity. The anti-cancer activity of NK cells and cytotoxic T cells is done through activating and inhibiting signal pathways.

Chimeric antigen receptor (CAR) T-cell therapy will change the way cancer is being treated. In the second half of 2017, the first two drugs in this new class of therapy were approved. Autologous T-cells that have been re-engineered can resist the immunosuppressive effects of tumors. The approved CAR-T therapies are directed against CD19 antigens and are approved to treat B-cell lymphoma and acute lymphocytic leukemia’s, both B-cell mediated diseases. The process involved engineering autologous antigen presenting cells removed from the patient and run through a manufacturing process that takes 17 to 29 days depending on the drug before being infused back into the patient. There are over 200 clinical trials underway with CAR-T therapeutics, some trials in combination with already approved checkpoint inhibitors. The autologous therapies are patient-specific personalized treatments. The costs are staggering for these therapies, with treatments for the drug alone costing hundreds of thousands of dollars. That does not include the costs for other chemotherapies, hospital inpatient, and ICU care costs. Hospitals and clinics running the trials have experienced doctors and nurses that know how to handle this therapy. Expanding to new treatment arenas will be a challenge.

Research advances in combination trials targeting more than one pathway may increase response rates over single targeted agents. If a combination product is produced by one company, it could be priced more competitively than targeted agents developed and marketed through a competitors’ alliance.

New approaches to adoptive T-cell therapies remain a hurdle, but the ultimate goals of increasing overall survival are not insurmountable. Changes in standards-of-care may limit access to patients for clinical trials for these new therapies.

Key Issues Addressed

  • What adoptive T-cell (CAR-T & TCR) therapies are in development and for what indications?
  • What products and indications will be launched in the next 7 years?
  • Who is investing in the development of adoptive T-cell therapies, at what phase, and at what level of deal funding?
  • What are some of the cost implications for adoptive T-cell therapies, especially when combined with other immuno-oncology therapies?
  • What are the challenges to development and commercialization of adoptive T-cell therapies?
  • What challenges do payors face related to the high cost of specialty therapeutics?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Key Takeaway

Scope and Segmentation

Key Questions this Study will Answer

Executive Summary—Market Snapshot

Executive Summary—Market Snapshot (continued)

8 Big Market Themes for Immuno-oncology Therapies

Hematological Cancers Dominate the Pipeline

Game Changing Companies

Investors Pour in Significant Funds

Key 2017 Predictions—Adoptive T-cell Therapy Market

Key Methodology

Adoptive T-cell Therapy Drug Classes

Timeline of Adoptive T-cell Product Evolution

Timeline of Adoptive Immuno-oncology Product Approvals

Competitive Landscape—Target Segments

Competitive Landscape—Target Product Counts

Adoptive T-cell Therapy Segmentation

Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells)

Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells) (continued)

Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells) CR

Competitive Landscape—T-cell Receptor (TCR) Segment

CAR-T Product Dashboard

CAR-T Product Dashboard (continued)

TCR Product Dashboard

Opportunities in this Market

Challenges for this Market

Potential Game Changing Immuno-oncology Therapies

Overall Environmental Impact Factors

Immuno-oncology Area Product Patent Expirations

Opportunities in this Market—Escalating Drug Costs

Adoptive T-cell Therapy Payor Environment

J-Codes, Annual Costs and US Payors

Adoptive T-cell Therapies—On-Label Reimbursement Path

Reimbursement Pathway—Off-Label: Medicare

Reimbursement Pathway—Off-Label: Commercial Payors

Reimbursement Pathway—Off-Label: Commercial Payors (continued)

A Snapshot of Global Drug Price Control Methods

Pitfalls to Avoid

Companies to Watch

Companies to Watch (continued)

Adoptive T-cell Therapy Forecast—2022 ($3.9 Billion) Forecasts by Product

Immuno-oncology Milestones

Immuno-oncology Milestones (continued)

Deal and Financing—Adoptive T-cell Therapies

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Deal and Financing—Adoptive T-cell Therapies (continued)

Key Conclusions

New Market Opportunities—Adoptive T-cell Therapies

The Last Word—3 Big Predictions

Legal Disclaimer

Pipeline Analysis—CAR-T Segment, Products in Development

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—CAR-T Segment, Products in Development (continued)

Pipeline Analysis—T-cell Receptor Segment, Products in Development

Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)

Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)

Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)

Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)

Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)

Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)

Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)

Pipeline Analysis—T-cell Receptor Segment, Products in Development (continued)

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Immuno-oncology refers to drugs that are used to stimulate the human immune system to target the fight against cancer. The immune system is capable of recognizing and eliminating foreign substances, including tumor cells. Tumors have, however, been able to escape detection by the immune system. There are drugs that can empower the immune system cells to attack tumor cells. Natural Killer (NK) cells are the main cells involved in the natural immune response. Once an immune response is initiated, the immune response can be sustained through memory, called adaptive immunity. Cytotoxic T cells are the main cells involved with adaptive immunity. The anti-cancer activity of NK cells and cytotoxic T cells is done through activating and inhibiting signal pathways. Chimeric antigen receptor (CAR) T-cell therapy will change the way cancer is being treated. In the second half of 2017, the first two drugs in this new class of therapy were approved. Autologous T-cells that have been re-engineered can resist the immunosuppressive effects of tumors. The approved CAR-T therapies are directed against CD19 antigens and are approved to treat B-cell lymphoma and acute lymphocytic leukemia’s, both B-cell mediated diseases. The process involved engineering autologous antigen presenting cells removed from the patient and run through a manufacturing process that takes 17 to 29 days depending on the drug before being infused back into the patient. There are over 200 clinical trials underway with CAR-T therapeutics, some trials in combination with already approved checkpoint inhibitors. The autologous therapies are patient-specific personalized treatments. The costs are staggering for these therapies, with treatments for the drug alone costing hundreds of thousands of dollars. That does not include the costs for other chemotherapies, hospital inpatient, and ICU care costs. Hospitals and clinics running the trials have experienced doctors and nurses that know how to handle this therapy. Exp
More Information
No Index No
Podcast No
Lightbox Content World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019
Author Barbara Gilmore
Industries Healthcare
WIP Number MC55-01-00-00-00
Is Prebook No
GPS Codes 9562-B1,9568-B1,9571-B1,9573-B1,9600-B1,9611-B1,9627-B1,99BF-B1,99C1-B1,99C6-B1,9A41-B1,9A42-B1,9A43-B1,9A44-B1,9A4E-B1,9A50-B1